Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: VPS52 (ImmuneEditome ID:6293)

1. Gene summary of enriched editing regions for VPS52

Gene summary

Gene information	Gene symbol	VPS52
	Gene ID	6293
	GeneSynonyms	ARE1\|SAC2\|SACM2L\|dJ1033B10.5
	GeneCytomap	6p21.32
	GeneType	protein-coding
	GeneDescription	vacuolar protein sorting-associated protein 52 homolog\|SAC2 suppressor of actin mutations 2-like protein\|VPS52, GARP complex subunit\|vacuolar protein sorting 52 homolog
	GeneModificationdate	20230329
	UniprotID	Q8N1B4;E9PI03;A0A0G2JIG2;Q4VXZ2
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr6:33260232-33261429:-	ENST00000471309.1	ENSG00000223501.7	VPS52	ncRNA_intronic	AluSx1,AluSx,AluJr4,L1MA1,(T)n	chr6:33260232-33261429:-.alignment
chr6:33260232-33261429:-	ENST00000478934.4	ENSG00000223501.7	VPS52	ncRNA_intronic	AluSx1,AluSx,AluJr4,L1MA1,(T)n	chr6:33260232-33261429:-.alignment
chr6:33260232-33261429:-	ENST00000493674.4	ENSG00000223501.7	VPS52	ncRNA_intronic	AluSx1,AluSx,AluJr4,L1MA1,(T)n	chr6:33260232-33261429:-.alignment
chr6:33260232-33261429:-	ENST00000495981.4	ENSG00000223501.7	VPS52	ncRNA_intronic	AluSx1,AluSx,AluJr4,L1MA1,(T)n	chr6:33260232-33261429:-.alignment

Top

2. Tumor-specific enriched editing regions for VPS52

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000223501.7,VPS52	THCA	EAG	3.9937e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr6:33260232-33261429:-	ESCA	Path	EER	7.6064e-03	3.7540e-02	0.2104
ENSG00000223501.7,VPS52	ESCA	Path	EAG	7.5636e-03	3.6201e-02	0.2119
ENSG00000223501.7,VPS52	THCA	Path	EAG	1.2258e-02	1.0788e-02	0.1446

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for VPS52

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for VPS52

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000223501.7,VPS52

THYM

EAG

MEX

ENSG00000073921.13

chr11

85959036:85959060:85960674:85960777:85976622:85976682:85981128:85981228

0.3250

3.2147e-02

9.1095e-06

0.4684

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G1;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL1;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

PICALM

Dendritic_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000204954.5

chr12

103956630:103956738:103950201:103951630:103950201:103953534

-0.4344

3.8757e-03

1.5900e-05

-0.4190

ACIN1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184

Macrophages_M1

GSVA_HALLMARK_HEDGEHOG_SIGNALING

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000136699.15

chr2

130157360:130157396:130161185:130161272:130164373:130164445

0.3717

6.2190e-03

5.6338e-06

0.4944

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL1;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Mast_cells_resting

GSVA_HALLMARK_E2F_TARGETS

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000136286.10

chr7

44966072:44966280:44966757:44966838

0.2876

3.1182e-02

1.1232e-04

0.4067

ADAR;BUD13;CELF2;EIF4A3;FBL;FUS;GTF2F1;HNRNPA1;MSI2;NOP56;PRPF8;SRSF1;TAF15;TARDBP;TROVE2;U2AF2;ZNF184

Mast_cells_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000159596.6

chr1

45688195:45688275:45690973:45691110:45693203:45693845

0.3566

1.4733e-02

5.6422e-06

0.4676

ACIN1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184

Macrophages_M1

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000100949.10

chr14

24270836:24271169:24271486:24271510

-0.4148

7.7353e-03

1.2884e-05

-0.4230

ADAR;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28;LIN28B;LSM11;MOV10;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000163001.7

chr2

55543937:55544074:55544906:55545075

0.3607

2.0359e-02

4.7943e-06

0.4414

ACIN1;ADAR;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184

Macrophages_M1

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000178950.12

chr4

867346:867432:868538:868685:870710:870904

0.3673

1.3646e-02

2.5237e-05

0.4138

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL1;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Macrophages_M1

GSVA_HALLMARK_E2F_TARGETS

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000149187.13

chr11

47468283:47468891:47472190:47472356

-0.3222

1.8984e-02

1.0986e-05

-0.4897

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G1;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL1;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Mast_cells_resting

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

ENSG00000223501.7,VPS52

THYM

EAG

ENSG00000076928.13

chr19

41896376:41896482:41897314:41898113:41898441:41898587

-0.3521

2.6931e-02

1.2311e-05

-0.4279

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL1;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Mast_cells_resting

GSVA_HALLMARK_E2F_TARGETS

More results

Top

5. Enriched editing regions and immune infiltration for VPS52

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000223501.7,VPS52	BLCA	EAG	Monocytes	4.6754e-02	0.1797
chr6:33260232-33261429:-	BRCA	EER	Dendritic_cells_activated	4.9019e-02	0.0914
ENSG00000223501.7,VPS52	BRCA	EAG	Dendritic_cells_activated	4.9820e-02	0.0911
ENSG00000223501.7,VPS52	CESC	EAG	Plasma_cells	1.2332e-02	0.2198
ENSG00000223501.7,VPS52	COAD	EAG	Plasma_cells	2.0827e-03	0.4567
ENSG00000223501.7,VPS52	DLBC	EAG	Mast_cells_resting	2.2230e-04	0.6738
chr6:33260232-33261429:-	ESCA	EER	Dendritic_cells_resting	2.6628e-02	0.2164
ENSG00000223501.7,VPS52	ESCA	EAG	Dendritic_cells_resting	2.7018e-02	0.2158
chr6:33260232-33261429:-	GBM	EER	Neutrophils	3.4611e-02	-0.2512
ENSG00000223501.7,VPS52	GBM	EAG	Neutrophils	3.4611e-02	-0.2512
ENSG00000223501.7,VPS52	HNSC	EAG	T_cells_CD4_naive	1.2851e-02	0.3681
ENSG00000223501.7,VPS52	KIRC	EAG	T_cells_regulatory_(Tregs)	3.5627e-02	0.2104
ENSG00000223501.7,VPS52	KIRP	EAG	Mast_cells_resting	2.1932e-02	-0.1915
ENSG00000223501.7,VPS52	MESO	EAG	B_cells_naive	2.5339e-03	0.4880
chr6:33260232-33261429:-	OV	EER	Macrophages_M1	2.0283e-02	0.1710
ENSG00000223501.7,VPS52	OV	EAG	Macrophages_M1	2.0283e-02	0.1710
ENSG00000223501.7,VPS52	PAAD	EAG	T_cells_regulatory_(Tregs)	4.5634e-02	-0.3306
ENSG00000223501.7,VPS52	PRAD	EAG	Mast_cells_activated	2.6358e-05	0.2114
ENSG00000223501.7,VPS52	SKCM	EAG	Dendritic_cells_activated	2.4866e-02	0.1544
chr6:33260232-33261429:-	STAD	EER	Mast_cells_activated	2.4668e-02	0.1561
ENSG00000223501.7,VPS52	STAD	EAG	Mast_cells_activated	2.1450e-02	0.1598
ENSG00000223501.7,VPS52	TGCT	EAG	T_cells_follicular_helper	1.4566e-02	-0.4039
ENSG00000223501.7,VPS52	THCA	EAG	Macrophages_M2	2.2521e-03	-0.1726
ENSG00000223501.7,VPS52	THYM	EAG	Macrophages_M1	1.5192e-04	0.3717
chr6:33260232-33261429:-	UCEC	EER	Dendritic_cells_activated	2.1604e-02	0.2582
ENSG00000223501.7,VPS52	UCEC	EAG	Dendritic_cells_activated	2.1604e-02	0.2582
ENSG00000223501.7,VPS52	UCS	EAG	Neutrophils	1.9591e-02	0.4935
ENSG00000223501.7,VPS52	UVM	EAG	Monocytes	2.1580e-03	-0.4553

Top

6. Enriched editing regions and immune gene sets for VPS52

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000223501.7,VPS52	THYM	EAG	3.9470e-02	-0.2073	3.0731e-02	-0.2173	2.5639e-03	0.2999	1.0558e-04	0.3798

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000223501.7,VPS52	BLCA	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	6.0098e-03	0.2464
ENSG00000223501.7,VPS52	BRCA	GSVA_HALLMARK_APOPTOSIS	EAG	2.0124e-06	0.2185
chr6:33260232-33261429:-	BRCA	GSVA_HALLMARK_APOPTOSIS	EER	1.8599e-06	0.2192
ENSG00000223501.7,VPS52	CESC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	2.7068e-02	0.1947
ENSG00000223501.7,VPS52	COAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.1849e-02	0.3489
ENSG00000223501.7,VPS52	DLBC	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	1.2034e-03	0.6101
chr6:33260232-33261429:-	ESCA	GSVA_HALLMARK_APOPTOSIS	EER	9.5288e-04	0.3178
ENSG00000223501.7,VPS52	ESCA	GSVA_HALLMARK_APOPTOSIS	EAG	9.5047e-04	0.3179
chr6:33260232-33261429:-	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	3.0156e-02	0.2575
ENSG00000223501.7,VPS52	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	3.0156e-02	0.2575
ENSG00000223501.7,VPS52	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.4172e-03	0.3149
ENSG00000223501.7,VPS52	KIRP	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	2.5558e-03	0.2504
ENSG00000223501.7,VPS52	LAML	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.1060e-02	0.3192
ENSG00000223501.7,VPS52	LGG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.9893e-02	0.1388
ENSG00000223501.7,VPS52	LIHC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	6.1472e-03	-0.2574
ENSG00000223501.7,VPS52	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.8513e-02	-0.1915
ENSG00000223501.7,VPS52	MESO	GSVA_HALLMARK_PEROXISOME	EAG	2.9010e-02	-0.3641
chr6:33260232-33261429:-	OV	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.2372e-06	0.3486
ENSG00000223501.7,VPS52	OV	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.2372e-06	0.3486
ENSG00000223501.7,VPS52	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	1.8836e-02	0.3844
ENSG00000223501.7,VPS52	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.6204e-02	0.3990
ENSG00000223501.7,VPS52	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	9.9385e-05	0.1960
ENSG00000223501.7,VPS52	SARC	GSVA_HALLMARK_P53_PATHWAY	EAG	2.3129e-04	0.4852
ENSG00000223501.7,VPS52	SKCM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.1822e-03	0.2218
ENSG00000223501.7,VPS52	STAD	GSVA_HALLMARK_HYPOXIA	EAG	1.5603e-03	0.2185
chr6:33260232-33261429:-	STAD	GSVA_HALLMARK_HYPOXIA	EER	1.4817e-03	0.2195
ENSG00000223501.7,VPS52	TGCT	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	1.0299e-02	0.4223
ENSG00000223501.7,VPS52	THCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	2.1241e-05	0.2386
ENSG00000223501.7,VPS52	THYM	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	3.0368e-06	0.4496
ENSG00000223501.7,VPS52	UCS	GSVA_HALLMARK_P53_PATHWAY	EAG	9.4929e-03	0.5399

Top

7. Enriched editing regions and drugs for VPS52

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000223501.7,VPS52	BLCA	ATRA	EAG	7.5182e-03	0.2399
ENSG00000223501.7,VPS52	BRCA	BIBW2992	EAG	9.7652e-03	0.1201
chr6:33260232-33261429:-	BRCA	BIBW2992	EER	9.5101e-03	0.1205
ENSG00000223501.7,VPS52	CESC	GDC0941	EAG	2.4507e-03	-0.2645
ENSG00000223501.7,VPS52	DLBC	GDC.0449	EAG	6.4389e-04	0.6353
ENSG00000223501.7,VPS52	KIRC	MG.132	EAG	2.4475e-05	-0.4104
ENSG00000223501.7,VPS52	KIRP	GDC0941	EAG	8.5770e-05	-0.3225
ENSG00000223501.7,VPS52	LAML	BIBW2992	EAG	4.4195e-03	0.3886
ENSG00000223501.7,VPS52	LGG	BIBW2992	EAG	2.0835e-02	-0.1476
ENSG00000223501.7,VPS52	LIHC	Cisplatin	EAG	2.1170e-03	-0.2875
ENSG00000223501.7,VPS52	LUSC	AP.24534	EAG	2.4599e-03	0.2447
ENSG00000223501.7,VPS52	MESO	GDC0941	EAG	4.2601e-02	-0.3398
chr6:33260232-33261429:-	OV	MG.132	EER	1.4604e-04	-0.2764
ENSG00000223501.7,VPS52	OV	MG.132	EAG	1.4604e-04	-0.2764
ENSG00000223501.7,VPS52	PCPG	Embelin	EAG	1.5067e-02	0.4326
ENSG00000223501.7,VPS52	PRAD	Cytarabine	EAG	6.8827e-07	0.2486
ENSG00000223501.7,VPS52	SARC	CI.1040	EAG	4.7632e-03	-0.3820
ENSG00000223501.7,VPS52	SKCM	AG.014699	EAG	4.2177e-02	0.1400
ENSG00000223501.7,VPS52	STAD	GSK269962A	EAG	8.1361e-03	-0.1839
chr6:33260232-33261429:-	STAD	GSK269962A	EER	5.5380e-03	-0.1926
ENSG00000223501.7,VPS52	TGCT	Embelin	EAG	2.9061e-02	0.3640
ENSG00000223501.7,VPS52	THCA	CI.1040	EAG	2.1834e-07	-0.2888
ENSG00000223501.7,VPS52	THYM	ABT.263	EAG	4.0867e-07	0.4831
chr6:33260232-33261429:-	UCEC	GW.441756	EER	1.0410e-02	0.2867
ENSG00000223501.7,VPS52	UCEC	GW.441756	EAG	1.0410e-02	0.2867
ENSG00000223501.7,VPS52	UCS	Etoposide	EAG	6.0153e-03	0.5662
ENSG00000223501.7,VPS52	UVM	JNK.9L	EAG	6.9665e-03	0.4056

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType